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Abstract 
 Leishmaniasis is a neglected disease that affects mainly the poorest and most vulnerable 
populations in developing countries. Currently, high rates of clinical failures have been reported 
associated with the classical treatments like miltefosine. Giardiasis is the most common 
parasitic diarrheal disease affecting humans. The first-line nitroimidazoles drugs were found to 
have relevant side effects and drug resistance to compounds have been reported. Trichomoniasis 
is a sexual transmitted parasitosis that increases the risk of HIV transmission and leads to 
adverse outcomes of pregnancy. Treatment options are in this case reduced to nitroimidazole 
compounds.  For all the described parasitosis the search for new medicines seems mandatory. 
 Marine organisms such as cyanobacteria and sponges are recognized as source of 
compounds promising for drug discovery. In Portugal, the Interdisciplinary Centre of Marine 
and Environmental Research (CIIMAR) hosts a cyanobacteria culture collection (LEGE culture 
collection) composed manly by strains isolated from the Portuguese coast. At the Department of 
Chemistry Giacomo Ciamician, Alma Mater Studiorum at the University of Bologna, Italy, 
studies concerning the antiparasitic potential of natural based compounds isolated from 
organisms such as sponges have been performed. Considering the bioactive potential of 
cyanobacteria and compounds of the University of Bologna, allied with the need for new drugs 
against major human parasites, we aimed with this work to study the potential of marine 
cyanobacteria and natural based compounds as antiparasitic for visceral leishmaniasis 
(Leishmania infantum), giardiasis (Giardia duodenalis) and trichomoniasis (Trichomonas 
vaginalis).  
 Cyanobacteria extracts obtained from lyophilized biomass, extracts from the LEGE 
culture collection and marine natural based compounds from the University of Bologna, were 
tested for toxicity against L. infantum promastigotes, and Giardia duodenalis and. Trichomonas 
vaginalis trophozoites. The 3- (4,5 dimethylthiazol-2-yl) - 2,5-diphenyl tetrazolium bromide-
212 (MTT) assay was applied in order to verify an antiparasitic effect. The results showed that 
Leishmania infantum was affected by the cyanobacteria extracts of the strains LEGE06099, 
LEGE06102 and LEGE07167, Giardia duodenalis was inhibited by the strains LEGE06108 and 
LEGE07175 and no significant toxic effects were registered to Trichomonas vaginalis. The 
cyanobacteria strains tested included the picoplanktonic forms of the genera Cyanobium, 
Synechocystis and Synechococcus and the filamentous forms Leptolyngbya. Although 
cyanobacteria have already being studied in antiparasitic studies, there are no references 
concerning those genera. In this sense, this study represents a contribution to broaden the range 
of cyanobacteria from which new antiparasitic compounds might be isolated. Natural based 
compounds were only tested for Giadia duodenalis and Trichomonas vaginalis. For these 
parasites only a slight reduction in viability was registered with compound AQ1812f27-28 in 
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Giardia duodenalis and compounds AQ1897f26-33 and AQ1906f33-42 for Trichomonas 
vaginalis. 
 The results obtained in the present study although preliminary, allow us to confirm the 
interest of these picoplanktonic and filamentous cyanobacteria genera as a source of 
antiparasitic compounds. Further studies using other viability assays are needed to confirm their 
potential antiparasitic effect. 
 
Key words: Giardia duodenalis, Leishmania infantum, marine cyanobacteria, marine natural 
based compounds, MTT, Trichomonas vaginalis. 
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Resumo 
 A leishmaniose é uma parasitose que afeta principalmente as populações mais pobres 
dos países em desenvolvimento. Atualmente, têm sido verificadas falhas com os tratamentos 
clássicos como a miltefosina. A giardíase é a doença parasítica diarreica que mais afeta o 
Homem. Efeitos secundários relevantes e resistência a drogas comuns como os nitroimidazóis 
têm sido descritos. A tricomoníase é uma parasitose de transmissão sexual que aumenta o risco 
de contágio por HIV e conduz a resultados adversos na gravidez. As opções de tratamento estão 
neste caso, limitados aos nitroimidazóis. Para todas estas parasitoses a pesquisa e 
desenvolvimento de novas terapias mostra-se fundamental.  
Os organismos marinhos, tais como cianobactérias e esponjas são reconhecidos como 
fontes promissoras de compostos com atividade terapêutica. Em Portugal, o Centro 
Interdisciplinar de Investigação Marinha e Ambiental (CIIMAR) possui uma coleção  de 
estirpes de cianobactérias maioritariamente isoladas do litoral português (coleção de culturas 
LEGE). No Departamento de Química Giacomo Ciamician, Alma Mater Studiorum da 
Universidade de Bolonha, Itália, estudos sobre o potencial antiparasitário de compostos 
baseados em produtos naturais isolados de organismos como esponjas têm sido realizadas. 
Considerando o potencial bioativo de cianobactérias e compostos da Universidade de Bolonha, 
aliado com a necessidade de novas drogas contra parasitoses comuns em humanos, foi objetivo 
deste trabalho estudar o potencial de cianobactérias marinhas e compostos baseados em 
produtos naturais como antiparasíticos para a leishmaniose visceral (Leishmania infantum), 
giardíase (Giardia duodenalis) e tricomoníase (Trichomonas vaginalis).  
 Extratos de cianobactérias obtidos a partir de biomassa liofilizada, extratos da coleção 
cultura LEGE e compostos da Universidade de Bolonha, foram testados quanto à sua toxicidade 
contra promastigotas de Leishmania infantum e trofozoítos de Giardia duodenalis e 
Trichomonas vaginalis. O ensaio de MTT foi aplicado a fim de verificar um efeito 
antiparasítico. Os resultados mostraram que Leishmania infantum foi a mais afetada pelos 
extratos de cianobactérias, neste caso pelas estirpes LEGE06099, LEGE06102 e LEGE07167, 
seguida, de Giardia duodenalis pelas estirpes LEGE06108 e LEGE07175. Para Trichomonas 
vaginalis não foi registado efeito tóxico para nenhum dos produtos testados. As estirpes de 
cianobactérias incluídas no estudo pertencem a formas picoplanctônicas dos géneros 
Cyanobium, Synechocystis e Synechococcus e a formas filamentosas do género Leptolyngbya.  
Apesar de existirem estudos relativos ao potencial antiparasítico de cianobactérias, não há 
referências aos géneros mencionados.  Os compostos baseados em produtos naturais foram 
apenas testados para Giadia duodenalis e Trichomonas vaginalis. Foi registado uma pequena 
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redução na viabilidade com o composto AQ1812f27-28 na Giardia duodenalis e para a 
Trichomonas vaginalis com os compostos AQ1897f26-33 and AQ1906f33-42. 
  Os resultados obtidos neste estudo, embora preliminares, permite-nos confirmar o 
interesse destas cianobactérias filamentosas e picoplânctonicas, como uma fonte de compostos 
antiparasíticos. Mais estudos usando outros testes de viabilidade são necessários para confirmar 
o potencial efeito antiparasitico.  
 
  Palavras chave: cianobactérias marinhas, compostos marinhos naturais, Giardia duodenalis, 
Leishmania infantum, MTT, Trichomonas vaginalis. 
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1. Introduction  
 The planet Earth is covered by 70% of water in which 96% are oceans. Considered the 
“mother of origin life”, oceans are the source of a wide range of bioactive natural products that 
are mainly produced by organisms such as sponges (37%), algae (9%) and echinoderms (6%) 
(Gerwick and Moore 2012). Marine organisms, through evolution, had to develop 
characteristics to cope with the changes in the environment, namely extreme conditions of 
temperature and pressure. Many of these adaptions resulted in the production of compounds that 
revealed interesting activities in the pharmacological field namely in deadly diseases such as 
cancer, acquired immune deficiency syndrome (AIDS) and arthritis (Imhoff et al., 2011). In 
fact, several marine compounds were approved by FDA (Food and Drug Admnistration) and are 
currently available to the public as drugs. As an example, Cytosar-U® (1969) or Halaven® 
(2010) are a trademark where the bioactive compound was found in sponges and now are used 
to treat leukemia and metastatic breast cancer, respectively; or even Adcetris®(2011) in which 
the compound was discovered from a symbiotic relationship between a mollusk and a 
cyanobacterium and is now a medicine to Hodgkin's disease. 
1.1 Cyanobacteria 
 Cyanobacteria, also known as cyanophyta, are a phylum from the Eubacteria Domain 
(Castenholz et al., 2001).These photosynthetic prokaryotes captures sunlight using clorophyll a 
and phycocyanin, a bluish pigment that was responsible for the name of these group of 
organisms (Whitton and Potts, 2007). Through their photosynthetic activities, 2 billion years 
ago, cyanobacteria played a major role in creating the atmosphere as we know nowadays. In 
fact, they were responsible for the accumulation of oxygen in the early atmosphere, which lead 
to our oxygenic environment (Hartman, 1998).  
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 Cyanobacteria are found in a wide range of habitats, from terrestrial to aquatic ones, and 
even in environments with extreme conditions such as extreme temperatures (Wieland, 2000). 
Due to a long evolution period and adaptation to different environmental conditions, 
cyanobacteria developed mechanisms of adaptation that include the production of several 
secondary metabolites.  
In the marine environment cyanobacteria occur as free-living organisms in open ocean 
or near shores, as benthic forms along the maritime coasts and as symbiotic forms with animals 
such as sponges (Paerl et al., 2000). In this environment, cyanobacteria play an important 
ecological role thought the involvement in the primary production and in nitrogen fixation 
(Carpenter et al., 2004) and by offering food and shelter to many aquatic organisms (Paerl et al.,  
2000). 
 
1.1.1 Cyanobacteria Bioactive compounds 
 Secondary metabolites are chemicals produced by an organism in which a role in 
primary functions such as growth or reproduction has not been found (Campàs et al.,  2010). 
Even though they are not absolutely required for the survival of the organism, in cyanobacteria 
they are responsible for many functions such as nutrient storage (Istvánovics et al. 1993, Kaplan 
et al., 1988) defense (Nogueira et al. 2004) and allelopathy (Leão et al., 2009).  
 The high biodiversity of cyanobacteria in nature leads to a high diversity in a chemical 
level, which in turn gives to various and different secondary metabolites that can be potential 
bioactive compounds. From this group of organisms  a variety of bioactive secondary 
compounds, that includes alkaloides, peptides, lipopetides, amino acids and fatty acids is 
described (Burja et al., 2001), being cyanobacteria considered a good source of compounds for 
biotechnology aplications, namely pharmaceutical and therapeutic application (Dahm et al., 
2006; Dixit et al., 2013; Tan 2013). In fact, in the pharmacology field, compounds isolated from 
cyanobacteria were found  to have antibacterial (Jaki et al., 2000), antifungal (T. Shishido et al. 
2015), antiviral (Patterson et al., 1994), anticancer ( Gerwick et al., 1994), immunosuppressive 
(Koehn et al., 1992), algicide (Papke et al., 1997) antiparasitic (Burja et al., 2001) and 
antiplasmodial (Papendorf et al., 1998) potential. In this sense, in the last few years, 
cyanobacteria have been considered one of the most promising sources of natural compounds 
(Dixit et al., 2013). 
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1.2 Parasitology 
 All over the world, the diseases caused by parasites are a public health problem 
affecting about one billion people (WHO, 2015), with most of them being also neglected 
tropical diseases (Molyneux et al., 2016). Despite their main prevalence in tropical and 
subtropical regions, recent epidemiological studies about leishmaniasis have shown an 
increasing prevalence in Europe largely caused by an augment in international travel, difficulty 
eradicating leishmanial infection in AIDS patients, and the use of immunosuppressive 
medications (Torpiano et al., 2015). 
 
 In spite of the progress that has been made in the prevention, control and elimination of 
human parasitic diseases, there are however some limitations concerning the therapeutics 
namely due to parasite resistance and adverse effects on patients.   
 Three main parasitosis affecting humans worldwide are visceral leishmaniasis, 
giardiasis and trichomoniasis.  
 Concerning leishmaniasis, it is a parasitic disease with clinical presentations that vary 
from asymptomatic infection to cutaneous, mucocutaneous or visceral disease. 1.3 million new 
cases occur annually: 300 000 are visceral and 1 million are cutaneous or mucocutaneous 
(WHO, 2015). The estimated number of deaths from visceral leishmaniasis ranges from 20 000 
to 50 000 annually (Alvar et al., 2012). 
 Giardiasis is the most common non-bacterial and non-viral diarrheal diseases affecting 
humans worldwide (Escobedo et al.,  2015). Because of its link with poverty and the potential 
for dissemination through food and water supplies, giardiasis was included in the Neglected 
Disease Initiative, estimating that 280 million people are infected each year. 
 Trichomoniasis is a sexual transmitted parasitosis that increases the risk of human 
immunodeficiency virus (HIV) transmission and leads to adverse outcomes of pregnancy. In an 
approach for 2005, a total number of 248 million new cases cases of trichomoniasis were 
estimated in adults between the ages of 15 and 49 (WHO, 2011). 
 
1.2.1 Leishmaniasis 
Leishmaniasis continues to pose a major public health problem worldwide. It is a 
zoonotic, infectious and non-contagious disease caused by different species of protozoan 
parasites of the genus Leishmania (Class Kinetoplastida, Family Trypanosomatidae) and 
transmitted by the bite of a female phlebotomine sandfly. This disease presents itself in three 
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forms: mucosal (infection of macrophages in the naso-oropharyngeal mucosa), cutaneous 
(infection of macrophages in the dermis) and visceral (infection of macrophages throughout the 
reticuloendothelial system). It is recorded each year, nearly 2 million new cases of leishmaniasis 
in the world. The most severe form of the disease is the visceral leishmaniasis (VL), being 85-
90% of untreated cases fatal (Chappuis et al., 2007).  
 The specie Leishmania infantum is the etiologic agent of VL and has two forms of life: 
the amastigote stage, oval or spherical with no free flagellum, and the promastigote stage, 
elongated with a free flagellum.  
 Leishmania infantum is a digenetic parasite that completes his life cycle in two hosts: 
phlebotomine sandflies  (intermediate host), that hosts the promastigote stage, and a mammal 
(definitive host) where the amastigote stage of the parasite develops. 
The life cycle of the parasite begins when the intermediate host, the female sandfly 
(vector), bites the definitive host (vertebrate) already infected, ingesting the parasites in an 
amastigote form. Within the vector, the amastigotes migrate to the phlebotomine intestine where 
they differentiate into infective promastigotes and multiply (Bates, 2007). In the next blood 
meal, the infected females inoculated into the vertebrate host the promastigotes forms of the 
parasite, which in turn are rapidly phagocytosed by macrophages. After phagocytosis, parasite 
differentiate into amastigotes and proliferate to the point of causing the rupture of the infected 
macrophage and causing the release of amastigotes in vertebrate host's body (Almeida-Souza et 
al. 2016; Chan et al., 2005). The infected macrophages migrate to the subcutaneous tissues, to 
the liver, spleen, bone marrow and lymph nodes, leading to the development of cutaneous and 
V, respectively. Thus, the development of the disease depends on the parasite species's 
efficiency with respect to the amastigote differentiation as well as the immune response of the 
host (Barral et al. 1991; Grimaldi et al., 1996). 
 Visceral leishmaniasis is a disease with worldwide distribution, with 90% of human 
cases occuring in India, Sudan, Bangladesh, Nepal and Brazil. (Molyneux et al., 2016; WHO, 
2015). The number of cases of leishmaniasis are increasing worldwide. Some reasons are the 
lack of vaccines, difficulties in controlling the vectors and increasing the number of resistance 
to chemotherapy of parasites. The human VL caused by L infantum is a major public health 
problem in areas where canine leishmaniasis is endemic and dogs are the main reservoir of 
infection. The disease affects the vital organs of the body and is characterized by irregular 
attacks of fever, weight loss, anemia, and enlargement of spleen and liver (WHO, 2015).  
Malnutrition has been recognized as a risk factor and may explain why the disease is more 
prevalent among children in poor countries than in developed countries, despite high prevalence 
rates in canine populations. The human disease is also prevalent in immunosuppressed 
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individuals; with HIV patients being the predominant risk group  in southern Europe (Monge-
Maillo et al., 2014).  
 According to WHO, leishmaniasis is among the parasitic diseases that mostly disturb 
the public health, by the frequency, and especially the therapeutic difficulties and also the 
clinical sequels that may result (WHO, 2004).  
 Although therapy historically has relied on antimonials, the latest treatment options 
include amphotericin B, liposomal, paromomycin and miltefosine (Sinha et al,. 2014). 
Combinations of drugs showed positive results and can be a short term solution to delay or 
prevent the onset of resistance, increased efficiency, and shorten the treatment course (Alvar et 
al., 2006; Sundar et al., 2011). Miltefosine is a recognized oral agent to treat this parasitosis, but 
with limitations to the safety of use, presenting relevant toxicity and a high frequency of side 
effects (Coelho et al., 2014). 
 
1.2.2 Giardiasis 
 Giardiasis occurs worldwide, with a distribution more prevalent in developing countries 
where hygiene conditions are poor, favoring its spread in warm climates (WHO, 2012). This is 
also a zoonotic disease caused by the infectious protozoan parasite Giardia duodenalis (also 
known as Giardia intestinalis or Giardia lamblia, Class Zoomastigophora, Family 
Hexamitidae) considered the major diarrheal diseases found worldwide. Its transmission is 
fecal-oral route and is due to ingestion of water and food contaminated with protozoa in the 
form of cysts (infective form), or from person to person (hand contact with contaminated feces, 
anal sex). Giardiasis is the most common infection caused by protozoa in children throughout 
the world (Coles et al., 2009; Gardner et al., 2001). 
 Giardia (G. duodenalis, G. intestinalis) is a flagellate protozoan that survives under two 
distinct morphological forms - cyst and trophozoite. These organism prefer humid locals, with 
water at a temperature of 4-10ºC. Cysts can remain viable for more than a few months 
(deRegnier et al., 1989); although the boiling point and instantaneous freezing result in 
inactivation (Meyer et al., 1980). Although humans are the primary reservoir of the parasite, 
several animals transport different species, which can be transmitted to humans. Giardia have 
been isolated from various animal species, and by 1950 these isolates were considered  highly 
specific hosts as to be named according to the host species, e.g. G. bovis, G. felis, among others. 
However, only three distinct species managed to survive being G. duodenalis the species that 
infect humans and many other mammals (Filice, 1952).  
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 The Giardia duodenalis life cycle is composed of the two forms of the parasite 
transmitted by feces: cyst (infective form) and trophozoite. Cysts are ingested by fecal-oral 
route or through consumption of food and / or contaminated water. When the cysts are ingested, 
digestive enzymes leads to the release and excystation of trophozoites (each cyst producing two 
trophozoites). Trophozoites proliferation leads to acute giardiasis, with an incubation period of 
1 to 14 days (mean 7 days) and usually lasts 1 to 3 weeks. Symptoms include diarrhea, 
abdominal pain, flatulence, nausea and vomiting. In chronic giardiasis symptoms are recurrent 
and can lead to debilitation. Several studies have shown that chronic infection of Giardia during 
childhood can contribute to calorie protein malnutrition, vitamin A deficiency, iron deficiency 
anemia, zinc deficiency and poor cognitive and educational performance (Halliez et al., 2013). 
          In relation to treatment, the first-line drugs are nitroimidazoles, with the prototype, 
metronidazole, being the most common drug used worldwide (Miyamoto et al., 2013). 
Alternatives to these drugs include paromomycin, quinacrine, and furazolidone  (Escobedo et 
al., 2007). However some of these compounds have relevant side effects and single and multi-
drug resistance to compounds, including metronidazole have also been reported (Alves et al., 
2011) . 
 
 1.2.3 Trichomoniasis 
 Trichomoniasis is a sexually transmitted disease (STD) caused by the infectious 
protozoan parasite Trichomonas vaginalis (Class Zoomastigophorae, Family Trichomonadidae). 
Trichomoniasis is the most common STD non-viral in the world, with 170 million new cases 
occurring annually (Menezes et al., 2016). 
 Trichomonas vaginalis is a flagellate protozoan (10-23μm) of rounded shape that during 
its life cycle only possess the trophozoite stage. It has four flagella that produce motion and a 
fifth that can help with direction. Its high motility contributes to the pathogenicity. The 
Trichomonas vaginalis is in lower genital tract of women while most affected men hosts the 
parasite inside the penis. Trichomonas multiplies by binary division and does not have the form 
of cyst, thus do not survive well in the external environment. The parasite causes damage to the 
vaginal epithelium, leading to the formation of microscopic ulcers that increase the risk of 
contamination by other sexually transmitted diseases, including HIV, Human Papilloma Vírus 
(HPV), herpes, gonorrhea and chlamydia. 
 This parasite occurs worldwide, prevailed more among people with multiple sexual 
partners or other sexually transmitted diseases. Trichomoniasis is a sexual transmitted 
parasitosis so it is important that infected sexual partners perform treatment simultaneously. 
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Treatment options are in this case reduced to nitroimidazole compounds (Alves et al., 2011), 
which highlight the need to search for new therapies. 
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2. Objectives 
 It is imperative the search for new antiparasitic compounds, due to the great difficulty of 
finding drugs that ensure an efficient therapeutic action and are less toxic to the host, so 
different natural products are being investigated, including cyanobacteria and sponges 
compounds. 
 The Blue Biotechnology and Ecotoxicology group (BBE) at the Interdisciplinary Centre 
of Marine and Environmental Reasearch (CIIMAR) has been involved in the study of the 
bioactive potential of cyanobacteria isolated from the portuguese coast. From the cyanobacteria 
culture collection several strains have been studied and compounds have been isolated. As a 
result of these studies different bioactivities were described such as anticancer (Costa et al., 
2014; Freitas et al., 2016a; Freitas et al., 2016b), antimicrobial (Costa et al., 2014; Martins et 
al., 2008) and antiviric  (Lopes et al., 2011). Also the antiparasitic potential has been studied to 
a less extent, being a compound described as potential antimalarian (Compound under a patent 
process). Also, the Department of Chemistry Giacomo Ciamician, Alma Mater Studiorum at the 
University of Bologna, Italy has been performing studies concerning the antiparasitic potencial 
effect of natural based compounds isolated from organisms such as sponges (Cerisoli et al., 
2016b; Persico et al., 2011; Monari et al., 2015). In this sense, considering the bioactive 
potential of the cyanobacteria strains of the LEGE culture collection, and compounds of the 
University of Bologna, allied with the need for new drugs against major human parasites, the 
main aim of this thesis was: 
 
 - to study the potential of marine cyanobacteria isolated from the portuguese coast and 
natural based compounds as antiparasitic for visceral leishmaniasis (Leishmania infantum), 
giardiasis (Giardia duodenalis) and trichomoniasis (Trichomonas vaginalis). 
  
 
Considering this main goal, specific objectives were defined: 
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1. To perform a literature review concerning cyanobacteria antiparasitic activity; 
2. To culture  cyanobacteria strains in order to prepare extracts from freeze dried biomass; 
3. To perform culture optimization of the parasites Leishmania infantum, Giardia 
duodenalis and  Trichomonas vaginalis, in vitro; 
4. To perform a toxicological assay in vitro ( 3- (4,5 dimethylthiazol-2-yl) - 2,5-diphenyl 
tetrazolium bromide-212 - MTT assay) to evaluate the antiparasitic potential effect of 
extracts and compounds. 
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3. Materials and Methods  
 3.1 Literature review 
 In order to compile information concerning the antiparasitic potential of cyanobacteria a 
search for scientific papers and reviews was performed by using the databases ScienceDirect 
and PubMed, until June 2016. The search was conducted by using “cyanobacterial 
antiparasitic compounds, “antiprotozoal compounds, “cyanobacterial bioactive compounds, 
“cyanobacterial antileishmanial compounds, “cyanobacterial antimalarial compounds” as 
example of key words. 
 
 3.2 Cyanobacteria strains  
 In this work eight marine cyanobacteria strains were cultured under laboratory 
conditions in order to obtain biomass (Table I). From this strains crude extracts were prepared. 
This cyanobacteria strains were selected according to bioactive potential already described in 
previous studies. Also crude extracts from cyanobacteria strains that are being studied in 
ongoing studies for bioactivities were included in the antiparasitic assays (Table II).    
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Table I. Cyanobacteria strains cultured for extract preparation.  
Strain Species/ Genera Order Origin 
Culture 
medium 
LEGE 
06102 
Leptolyngbya halophile Oscillatoriales 
S. Bartolomeu do 
Mar 
Z8 + NaCl 
LEGE 
07167 
Leptolyngbya fragilis Oscillatoriales Lavadores Z8 + NaCl 
LEGE 
06113 
Cyanobium Chroococcales Aguda 
Z8 + NaCl 
 
LEGE 
07175 
Cyanobium Chroococcales Martinhal Z8 + NaCl 
LEGE 
06099 
Synechocystis salina Chroococcales Moledo Z8 + NaCl 
LEGE 
06108 
Synechocystis salina Chroococcales 
S. Bartolomeu do 
Mar 
Z8 + NaCl 
LEGE 
07163 
Pseudanabaena persicina Oscillatoriales  Z8 + NaCl 
LEGE 
06194 
Pseudanabaena sp. Oscillatoriales  Z8 + NaCl 
 
Table II – Marine cyanobacteria extracts of LEGE cyanobacteria culture collection included in this study. 
Strain Species/ Genera Order Origin 
LEGE 06014 Leptolyngbya sp. Oscillatoriales Arellho 
LEGE 06020 Leptolyngbya sp. Oscillatoriales Coxos 
LEGE 00038 Synechocystis sp. Chroococcales Mindelo 
LEGE 00041 Synechocystis sp. Chroococcales Espinho 
LEGE 06361 Leptolyngbya sp. Oscillatoriales Unknown 
LEGE 11428 Synechococcus sp. Chroococcales Unknown 
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Figure 1 – Culture of cyanobacteria. Left: after the inoculation (beginning of the culture). Right: after fifteen 
days. 
  
 3.3 Cyanobacteria Culture, lyophilisation and extraction 
 In order to obtain sufficient biomass for the antiparasistic assays, six cyanobacteria 
strains (Table I) were cultured under laboratory conditions. 
 Cyanobacteria strains were cultured following the procedures already optimized in the 
LEGE laboratory.  Briefly, cyanobacteria strains were incubated in the laminar flow chamber in 
six liter glass flasks containing 4  liters of nutrient Z8medium (with 20g/L NaCl) (Kotai 1972) 
and a 500 mL of cyanobacteria stock culture. Cultures were maintained under an aeration 
systems with controlled temperature conditions (25°C) and luminance (light cycles / dark 14h / 
10h). 
 When cultures reached the exponential growth stage, after approximately 30 days of the 
inoculation, visually recognized by the high concentration of biomass (Figure 1), the culture 
was harvested by centrifugation. 
  
 
 
 
 
  
  
 
 
 Cultures were centrifuged at 4,500 rpm, 4°C, 10 minutes. The supernatant was removed 
and the pellet washed with sterile distilled water and centrifuged again. The supernatant was 
removed one second time, and the pellet was placed in a flask collector to freeze at -20°. 
 Before lyophilisation, the concentrated biomass was placed at -80ºC. The frozen 
biomass was lyophilized for 4 days at -48ºC and then stored in a refrigerator. A stock culture of 
all cyanobacteria was maintained during this work in order to obtain biomass for the different 
bioassays. These cultures were performed by the inoculation process mentioned above, by 
removing a small sample of the culture and placing it in flasks with 100 ml of Z8 medium 
(20g/L NaCl). 
From the cultured cyanobacteria strains a crude extract was prepared by also following 
the procedure already optimized in the LEGE laboratory. Briefly, 1g of lyophilized material of 
each strain was extracted for 10 minutes with 50mL of a dichloromethane: methanol (2:1) 
solution by stirring periodically. The solution was them placed into a Bücher funnel, under 
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vacuum for filtration. At the end of the filtration the residual mass was collected and extracted 
for another 10 minutes. After extraction the solvents were evaporated in the rotary evaporator at 
-7 °C. The flask was then washed with a mixture of isooctane: ethanol (1:1, v/v) to dissolve the 
pellet, using ultrasounds, and transferred to a previously weighted 22 mL clear glass vial. The 
mixture was evaporated using N2. The glass vial was weighted again and the total mass of the 
crude extract calculated. The dry extract was dissolved in DMSO for the antiparasitic assays. 
Cyanobacteria extracts were tested against parasites at a final concentration of 1 µg/mL and 0,1 
µg/mL with DMSO at a final concentration of 1%.  
 
 3.4 Marine natural based compounds 
 In addition to the cyanobacterial natural extracts it was also evaluated the antiparasitic 
potential of several natural based compounds provided by Arianna Quintavalla, researcher at the 
Department of Chemistry Giacomo Ciamician, Alma Mater Studiorum, University of Bologna, 
Italy. 
 All these compounds are synthetic but their design was based on natural compounds. 
Indeed they have in common structural motifs, some of them with a marine origin, that have 
already shown bioactivity against protozoan and helminthic parasites (Persico et al., 2011); 
Trost et al, 2013). 
 The compounds tested in this study are listed in Table III and IV and their chemical 
basic structure belongs to: 
 -Peroxide derivatives (Persico et al., 2011; Sonawane et al., 2015a; Sonawane  et al., 
2015b) (Table III); 
  -Spiro oxindole derivatives (Monari et al., 2015a; Cerisoli et al., 2016a) (Table 
III) 
Compounds solubilized in DMSO were tested against Giardia duodenalis and 
Trichomonas vaginalis at a final concentration of 1 µg/mL as described in 3.5 and 3.6. 
Leishmania infantum assays were not performed as a demand of the authors.  
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Table III- Natural based compounds that were evaluated as potential antiparasitic with their chemical basic structure 
Compound 
name 
Basic structure 
 
Ref. 
AQ1972f39 
 
 
spirooxindole 
substructure and the a-
alkylidene-g-
butyrolactone moiet 
 
 
Cerisoli et 
al, 2015 
AQ1974f13 
 
 
spirooxindole 
substructure and the a-
alkylidene-g-
butyrolactone moiet 
 
Cerisoli et 
al, 2015 
LCL89R 
 
 
spirooxindole 
substructure and the a-
alkylidene-g-
butyrolactone moiet  
 
Cerisoli et 
al, 2015 
LCL168R 
 
 
spirooxindole 
substructure and the a-
alkylidene-g-
butyrolactone moiet 
 
Cerisoli et 
al, 2015 
LCL169R 
 
 
spirooxindole 
substructure and the a-
alkylidene-g-
butyrolactone moiet 
 
Cerisoli et 
al, 2015 
DS-23 
 
 
dioxanes derivated 
 
Sonawane 
et al 2015b 
DS-139 
 
 
dioxanes derivated 
 
Sonawane 
et al 2015b 
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DS-130 
 
 
dioxanes derivated 
 
Sonawane 
et al 2015b 
DS-131 
 
 
dioxanes derivated 
 
Sonawane 
et al 2015b 
DS-24 
 
 
dioxanes derivated 
 
Persico et 
al, 2011 
DS-215 
 
 
Endoperoxide derivated 
(artemisina bone) 
 
Sonawane 
et al 2015a 
Ds-217 
 
 
Endoperoxide derivated 
(artemisina bone) 
 
Sonawane 
et al 2015a 
DS-221 
 
 
Endoperoxide derivated 
(artemisina bone) 
 
Sonawane 
et al 2015a 
DS-222 
 
 
Endoperoxide derivated 
(artemisina bone) 
 
Sonawane 
et al 2015a 
AQ1963f50-
51 
 
 
spirocarbocyclic 
oxindoles 
 
 
Morani et 
al, 2015 
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AQ1964f43-
51 
 
 
spirocarbocyclic 
oxindoles 
 
 
Morani et 
al, 2015 
AQ1865f33-
38 
 
 
spirocarbocyclic 
oxindoles 
 
 
Morani et 
al, 2015 
AQ1851f23-
25 
 
 
spirocarbocyclic 
oxindoles 
 
 
Morani et 
al, 2015 
AQ1829f13-
16 
 
 
spirocarbocyclic 
oxindoles 
 
 
Morani et 
al, 2015 
AQ1812f27-
28 
 
 
spirocarbocyclic 
oxindoles 
 
 
Morani et 
al, 2015 
AQ1872f20-
24 
 
 
spirocarbocyclic 
oxindoles 
 
 
Morani et 
al, 2015 
AQ1893f44-
46 
 
 
spirocarbocyclic 
oxindoles 
 
 
Morani et 
al, 2015 
AQ1897f26-
33 
 
 
spirocarbocyclic 
oxindoles 
 
 
Morani et 
al, 2015 
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AQ1906f33-
42 
 
spirocarbocyclic 
oxindoles 
 
 
 
Morani et 
al, 2015 
AQ1880f48-
55 
 
 
spirocarbocyclic 
oxindoles 
 
 
Morani et 
al, 2015 
AQ1866f26-
30 
 
 
spirocarbocyclic 
oxindoles 
 
 
Morani et 
al, 2015 
AQ1846f18 
 
 
spirocarbocyclic 
oxindoles 
 
 
Morani et 
al, 2015 
 
 
Table IV – Natural based compounds that were evaluated as potential antiparasitic. 
Basic structure 
molecule 
Compound reference 
Peroxide 
derivates 
DS-23; DS-24; DS-130; DS-131; DS-139; 
DS-215; Ds-217; DS-221; DS-222 
 
Spiro oxindole 
derivates 
AQ1812f27-28; AQ1829f13-16; AQ1846f18; AQ1851f23-25; AQ1865f33-38; 
AQ1866f26-30; AQ1872f20-24; AQ1880f48-55; 
AQ1893f44-46; AQ1897f26-33; AQ1906f33-42; AQ1963f50-51; AQ1964f43-
51; 
AQ1972f39; AQ1974f13; LCL168R; LCL169R; LCL89R 
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 3.5 Parasites 
 The parasites included in this study were Leishmania infantum, Giardia duodenalis and 
Trichomonas vaginalis. Information concerning the strain reference, culture medium and 
incubation temperature is presented in Table V. All parasites were stored at -80ºC in complete 
culture medium with 10% DMSO. 
 
Table V – Parasites included in this study and summary of culture condition 
Species Strain Disease 
Temperature of 
incubation 
Metabolism 
Condition 
Culture 
Medium 
Leishmania 
infantum 
IMT 
151 
Visceral 
Leishmaniasis 
26ºC Aerobic 
RPMI + 
10% FCS 
Giardia 
duodenalis 
ATCC 
30888 
Giardisis 37ºC Anaerobic 
TSY-S-33 
modified 
Trichomonas 
vaginalis 
INSA 
157654 
Vaginal 
Trichomoniasis 
37ºC 
Facultative 
anaerobic; 
microaerofilic 
Diamond,T
YM 
 
  
3.5.1 Leishmania infantum  
For culturing and parasites maintenance, an 1 ml aliquot of promastigotes of L. infantum 
IMT 151 was poured into 9 mL RPMI GlutaMAX-I medium (Gibco, Life Tecnologies) medium 
supplemented with 10% fetal bovine serum, 50U/ml penicilin, 50 µg/mL streptomycin and 
25mM HEPES soidum salt (RPMI complete medium), pH7,4 in a 25cm
2
 flask (Orange 
Scientific's advanced, high-quality Tissue Culture). Parasites were maintained at 26ºC. 
 
 3.5.1.2 Growth curve determination 
 The characterization of parasite growth in vitro is fundamental to evaluate the 
compounds effect on parasite cultures. For growth curve determination, promastigotes of L. 
infantum IMT 151 were incubated at 5 x 10
6
 parasites/ml in RPMI complete medium 
supplemented with fetal bovine serum (10%) (Keister, 1983), at 26ºC. During 5 days, a daily 
quantification of parasite density was performed, in triplicate, by counting promastigotes in a 
Neubawer chamber and an estimative of viability was obtained by Trypan blue exclusion. 
Trypan blue is a blue dye often used as a quick test to evaluate the cellular viability. This dye 
enters the cell when cell membrane is damaged. Thus, after adding trypan blue to a cellular 
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suspension (1:1), viable cells do not stain while not viable cells acquire a blue color. This test 
was performed during cell counting for the determination of the growth curve and for the 
antiparasitic assays, to have a direct assumption of the viability of the parasites. Culture 
exponential phase was defined after growth curve determination.  
 
 3.5.1.3 Viability MTT assay 
The potential antiparasitic effect for Leishmania infantum was tested only with 
cyanobacteria strains referred on Table I. For viability assays Leishmania infantum 
promastigotes at a density of 1,5x10
6
 parasites/mL were cultured in 1 mL RPMI complete 
medium in 1,5ml eppendorfs. Cyanobacteria extracts and natural based compounds were added 
and incubated for 72 hours at 26 ºC. After incubation the viability assay using the 3- (4,5 
dimethylthiazol-2-yl) - 2,5-diphenyl tetrazolium bromide-212 (MTT) was carried out. These 
MTT assay conditions were a result of an optimization procedure also performed in this thesis. 
 The MTT assay (Mosmann, 1983) is a colorimetric assay that relies on the cellular 
reduction of tetrazolium salt  by mitochondrial dehydrogenases in viable cells. In solution, the 
MTT salt has a yellow color but, after reduction by mitochondrial dehydrogenases present in 
metabolically active cells yields formazan crystals purple. Subsequently, these crystals after 
dissolved with DMSO, absorb in the visible region, allowing spectrophotometrically quantitate 
the number of viable cells. Since formazan crystals are slightly soluble in the RPMI medium, it 
was necessary to remove this medium before incubation with the MTT. After incubation time 
with the cyanobacteria extracts, eppendorfs were centrifuge in order to concentrate the parasites. 
The culture medium was carefully removed and changed to a solution of PBS-Glicose (1:1).  
MTT was them added to each eppendorf to a final concentration of 0.02mg/mL and incubated 
for 4 hours.  After the MTT incubation, eppendorfs were centrifuged again and the PBS-Glicose 
aspired carefully. The formazan crystals were them solubilized with 100% DMSO and the 
absorbance was read at 550nm. Each assay was run in quadruplicate and three experiments were 
performed independently. As a positive control amphotericin B was tested at a concentration of 
0.1 µM. The negative control consisted in culture medium with 1% DMSO.  
 
 3.5.2 Giardia duodenalis 
 3.5.2.1 Parasite density optimization 
 An 1 ml aliquot containing trophozoites of Giardia duodenalis ATCC 30888 was 
poured into a Nunclon tube with TYI-S-33 modified medium (Keister, 1983)  supplemented 
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with 50U/ml penicilin, 50 µg/mL streptomycin and culture at 37ºC. After incubation for 48h, 
trophozoites were detached from the substracte by cooling on ice for 20 minutes and 
subcultured. Culture tubes were full completed with culture medium, in order to obtain an 
anaerobic environment.  
 For determination of the initial parasite density for viability tests, preliminary MTT 
assays were performed in 96 well plate with 300 µL medium/well and using three initial 
different concentrations, 2x10
4
parasites/mL, 5x10
4
parasites/mL and 1x10
5
 parasites/mL. After 
an incubation time of 24 hours, cells were incubated for 4 hours with MTT at a final 
concentration of 0.05mg/mL. After the incubation the medium was aspired, formazan crystals 
were solubilized with 100%DMSO and the absorbance was read at 550nm. These MTT assay 
conditions were a result of an optimization procedure also performed in this thesis. 
 
 3.5.2.2 Viability MTT assay 
Viability assays using Giardia duodenalis trophozoites were performed for all the 
cyanobacteria extracts and the natural based compounds presented above, at a density of 5x10
4
 
parasite/mL were seeded in a 96-wells plate, in triplicate. After 3 hours of cell adhesion to the 
plate, cyanobacteria extracts and natural based compounds were added and incubated for 24 
hours at 37 ºC.  After the incubation time, the culture medium was exchanged to PBS-Glicose 
(1:1), since the TSY-S-33 medium spontaneously reacts with the MTT. MTT was added to a 
final concentration of 0.05mg/mL and incubated for 4 hours. After the incubation the medium 
was aspired, formazan crystals were solubilized with 100% DMSO and the absorbance was read 
at 550nm. These assays were performed three times independently. The positive control 
consisted in 1% of metronidazole at a concentration of 0,856g/L. The negative control consisted 
in culture medium with 1% DMSO. During incubation the plates were maintained in a low-
oxygen environment achieved through a system of AnaerocultC (Merck) and by using an 
anaerobic jar. For cell counting the trypan blue assay was performed in order to infer about 
parasites viability before the MTT assay. 
  
 3.5.3 Trichomonas vaginalis 
 3.5.3.1 Growth curve determination 
 Growth curve determination of  Trichomonas vaginalis trophozoites was performed by  
incubating the parasites in Diamond-TYM medium (Green et al., 2012), at 37ºC, in 
microaerophilic conditions. During 3 days, a daily quantification of parasite density was 
performed, in triplicate, by counting trophozoites in a neubawer chamber and an estimative of 
viability was obtained by trypan blue exclusion.  
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 3.5.3.2 Viability MTT assay  
 The antiparasitic effect on Trichomonas vaginalis was tested with the cyanobacteria 
strains referred in Table I and with the natural based compounds referred in Table III. For 
viability assay Trichomonas vaginalis trophozoites at a density of 2,8x10
5
 parasites/mL were 
seeded in eppendorfs, in triplicate. Cyanobateria extracts and natural based compounds were 
added and incubated for 24hours at 37ºC. After incubation, eppendorfs were centrifuge at 1200 
rpm for 5 minutes at 10ºC. Culture medium was carefully exchanged to PBS-Glicose (1:1) with 
careful not to aspirate the trophozoites pellet. Parasites were then treated with 0.02mg/mL MTT 
final concentration, for 4 hours. After incubation with MTT, the eppendorfs were centrifuged 
and the medium was aspired carefully.  Formazan crystals were solubilized with 100% DMSO 
and the absorbance was read at 550nm. These assays were performed three times independently. 
The positive control consisted in 1% of metronidazole at a concentration of 0,856g/L. The 
negative control consisted in culture medium with 1 % DMSO. These MTT assay conditions 
were a result of an optimization procedure also performed in this thesis. 
3.6. Statistical analysis 
 Differences in the effect of cyanobacterial extract on parasite viability were analyzed 
with a general linear model, using parasite viability as dependent variable and treatment (levels: 
concentration of cyanobacterial extract, positive control and negative control) as fixed factor. 
The assumption of normality of model residuals was tested with a Shapiro-Wilks test. If 
residuals were not normal they were transformed using the Box-Cox function. If this 
transformation did not produce the intended effect, data would be analyzed with a generalized 
linear model, assuming that residuals follow a Gamma distribution. 
 Since the data were obtained from 3 independent assays with identical design, we also 
considered if the inclusion of 'assay' as a random factor in the model would significantly 
improve our model. For every single data set (parasite  cyanobacterial extract) the AIC value 
of a mixed effects model including 'assay' as random factor was compared to the AIC value of 
an equivalent fixed effects model, and the model with the lowest value was chosen. 
 After obtaining the suitable model for each case, we tested the effect of treatment with 
analysis of variance (for general linear models with only fixed effects) or analysis of deviance 
(for generalized linear models with only fixed effects or for any mixed effects models). If the 
effect of treatment was found to be statistically significant (p<0,05) we performed a post-hoc 
Tukey test for all the pairwise comparisons between treatment levels (Positive and negative 
control, and cyanobacterial extract). 
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 All these analysis were performed using the packages stats, MASS and lme4(Bates et al., 
2014) from the software R version 2.15.2 (R Core Team 2015). 
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4. Results and Discussion 
 4.1Antiparasitic potential of Cyanobacteria 
 In order to compile the information concerning studies related to the antiparasitic effects 
of cyanobacteria compounds, an extensive search for scientific papers was performed. From 
this search, papers concerning effects against Plasmodium falciparum (malaria), Leishmania 
species (leishmaniasis), Trypamosoma and Toxoplasma were found. For more easly present 
data, results concerning the different parasites are presented separately (Tables VI, VII and 
VIII). In Table VI it is presented the cyanobacteria compounds that were tested as 
antileishmanial. The cyanobacteria compounds that were tested as antiplasmodium by using 
the parasites that cause malaria, the Plasmodium falciparum, are presented at Table VII while 
the cyanobacteria compounds that were tested against Trypanossoma cruzi and Toxoplasma 
gondii are organized in Table VIII.   
 Most of the papers found are related to the parasite Plasmodium falciparum, the agent 
of the more severe form of malaria infection (Table VI). According to the 2014 WHO Malaria 
report (WHO, 2014)  it is estimated that 3.2 billion people are at risk of being infected with 
malaria and 1.2 billion are at high risk (>1 in 1000 chance of getting malaria in a year). In 
2013, 198 million cases of malaria were reported, with around 584 000 deaths. The treatment 
for malaria is still based on parasite chemotherapy with drugs such as quinine, mefloquine and 
artemisinin. However its poor tolerability and poor compliance, associated to an increasing 
resistance of the parasite against these drugs (Elfawal et al., 2015) has forced the research for 
effective new antiplasmodial agents.  
 Concerning the potential of cyanobacteria against Leishmania parasites, we found 
Leishmania donovani as the most evaluated species (Table VII). Leishmaniasis is also a 
deadly parasitic diseases with 200 000–400 000 people contracting the infection every year in 
developing countries. Miltefosine is a recognized oral agent to treat this parasitosis, but with 
limitations to the safety of use, presenting relevant toxicity and a high frequency of side 
effects (Coelho let al. 2014) and thus, the research for effective drugs remains essential.  
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 Studies involving Trypanossoma and Toxoplasma species were also found (Table VIII) 
namely with the specie Trypamossoma cruzi. Trypanossoma cruzi is the causing agent the 
human american trypanosomiasis, also known as chagas desease. It is estimated that about 6 
million to 7 million people worldwide are infected with Trypansosoma cruzi. The Chagas 
disease is found mainly in Latin American countries (WHO, 2016). Although drugs such 
benznidazole and also nifurtimox are effective they cause severe side effects and the cost of 
treatment f remains substantial. Also there is no vaccine against this disease, which leads to 
the search for new therapeutical agents (WHO, 2016).  
 
Looking through the Tables VI, VII and VIII it is notorious that most of the studies are 
related to filamentous cyanobacteria, namely of the genera Lyngbya and Oscillatoria. In fact, 
the majority of studies concerning marine cyanobacteria as producers of bioactive compounds 
with pharmacological potential, involved cyanobacteria that growth in high densities along the 
maritime shores of tropical and subtropical regions being the genera Lyngbya, Microcoleus, 
Oscillatoria, Schizothrix, Symploca and Trichodesmium the most referenced ones (Gerwick et 
al., 2008). Due to the massive growth of these cyanobacteria in natural conditions, little effort is 
applying in getting biomass. On the contrary there are numerous other genera that have not been 
studied in such detail, mainly because under natural conditions they occur in low densities. In 
this group it is included the picoplanktonic forms of the genera Cyanobium, Synechocystis and 
Synechococcus and the filamentous forms Leptolyngbya included in this study (Tables I and II) 
In this sense, this study represents a contribution to broaden the range of cyanobacteria from 
which new bioactive compounds might be isolated.  
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Table VI- Review of Cyanobacteria species/compounds tested against Leishmania parasites 
Compound Species 
Class of 
compound 
Assay IC50 Model tested Reference 
     
Venturamide B Oscillatoria sp. Cyclic peptides DNA fluorescence >19nM 
Leishmania 
donovani; 
Linington et al., 
2007 
     
Gallinamide A Schizothrix sp. Peptide - 9,3 µM L. donovani 
Linington et al., 
2007
 
     
Dragonamide 
E 
Lyngbya majusucla Lipopetide 
PicoGreen® fluorescence 
assay 
5,1 μM L. donovani 
Nunnery et al., 
2012 
     
Viridamide A 
Oscillatoria nigro-
viridis 
Lipopeptides DNA fluorescence 1.5 μM L. mexicana 
Nunnery et al., 
2012 
     
Venturamide 
A 
Oscillatoria sp 
cyclic 
hexapeptides 
Fluorimetric assay 20  µM L. donovani 
McPhail et al., 
2007 
     
Venturamide B Oscillatoria sp 
cyclic 
hexapeptides 
Fluorimetric assay 
> 19  
µM 
L. donovani 
McPhail et al., 
2007 
     
Herbamide B Lyngbya majusucla Lipopeptide - 5,9µM L. donovani 
Nunnery et al., 
2012 
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Coibacin A Oscillatoria sp Polyketide pLDH 2.4 μM L. donovani Marcy J et al., 2012 
     
Almiramides B L. majuscula Lipopeptides DNA fluorescence 
2.4 μM 
 
L. donovani Sanchez et al., 2010 
     
Almiramides C L. majuscula Lipopeptides DNA fluorescence 1.9 μM L. donovani Sanchez et al., 2010 
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Table VII- Review of Cyanobacteria species/compounds tested against Plasmodium falciparum parasites 
Compound  Cyanobacteria specie/genera Class of compound Assay IC50 Reference 
Calothrixins A Calothrix sp. - pLDH 58 nM Rickards et al., 1999 
Calothrixins B Calothrix sp. - pLDH 180 nM Rickards et al., 1999 
Venturamide B Oscillatoria sp. Cyclic peptides Dna-based microfluorimetric method 5,2 nM Linington et al., 2007 
Gallinamide A Schizothrix sp. Peptide - 8,4 µM Linington et al., 2007
 
Dragonamide E Lyngbya majusucla Lipopetide PicoGreen® fluorescence assay > 10 μM Nunnery et al., 2012 
Viridamide A Oscillatoria nigro-viridis Lipopeptides - 5,8  μM Nunnery et al., 2012 
Venturamide A Oscillatoria sp Cyclic hexapeptides Microfluorimetric assay 8,2  µM McPhail et al., 2007 
Venturamide B Oscillatoria sp Cyclic hexapeptides Microfluorimetric assay 5,2 µM McPhail et al., 2007 
Symplostatin 4 Symploca sp. Linear depsipeptide [3H]hypoxanthine assay 0.7±0.2mM Conroy et al., 2010 
Lagunamide A Lyngbya majusucla Cyclic depsipeptides [3H]hypoxanthine assay 0.19 µM Tripathi et al., 2011 
Lagunamide B Lyngbya majusucla Cyclic depsipeptides [3H]hypoxanthine assay 0.91 µM Tripathi et al., 2011 
Lagunamide C Lyngbya majusucla Cyclic depsipeptides [3H]hypoxanthine assay 0.29 µM Tripathi et al., 2011 
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Tumonic acids I Blennothrix cantharidomum Acylproline derivate Inhibition of quorum sensing activities 2 µM Clark et al., 2008 
Carmabin A Lyngbya majusucla Linear alkynoic lipopeptides Fluorometric method 4,3 µM McPhail et al., 2007 
Dragomabin Lyngbya majusucla Linear alkynoic lipopeptides Fluorometric method 6 µM McPhail et al., 2007 
Dragonamides A Lyngbya majusucla Linear alkynoic lipopeptides Fluorometric method 7,7 µM McPhail et al., 2007 
Ambigol C Fischerella ambígua - - 1,5µM Wright et al., 2005 
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  Table VIII - Review of Cyanobacteria species/compounds tested against Trypanosoma cruzi and Toxoplasma gondii parasites. 
Compound Species 
Class of 
compound 
Assay IC50 Model tested Reference 
Venturamide B Oscillatoria sp. Cyclic peptides 
Growth 
inhibition 
15.8 mM T.  cruzi Linington et al., 2007 
Nostodione A Nostoc commune Alkaloid 
Colorimetric 
assay 
85 µM 
Toxoplasma 
gondii 
McNulty et al., 2014 
Gallinamide A Schizothrix sp. Peptide - 16,9 µM T. cruzi Linington et al., 2007
 
Dragonamide E 
Lyngbya 
majusucla 
Lipopetide 
Colorimetric 
assay 
> 10 μM T. cruzi Nunnery et al., 2012 
Viridamide A 
Oscillatoria 
nigro-viridis 
Lipopeptides 
Growth 
inhibition 
1.1 μM T. cruzi Nunnery et al., 2012 
Venturamide A Oscillatoria sp 
cyclic 
hexapeptides 
Growth 
inhibition 
14,6  µM T. cruzi McPhail et al., 2007 
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Venturamide B Oscillatoria sp 
cyclic 
hexapeptides 
Growth 
inhibition 
15,8 µM T. cruzi McPhail et al., 2007 
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 4.2 Antiparasitic activity 
 The antiparasitic activity was evaluated using the MTT assay.  Since it is a colorimetric 
assay that relies on the cellular reduction of the tetrazolium salt in viable cells, it will be imply 
that higher metabolic activity indicate higher parasite viability, which in turn can be interpreted 
as an increase in parasites proliferation. 
  
 4.2.1 Leishmania 
 4.2.1.1 Culture Optimization 
 The conditions for the viability assay using Leishmania parasites, such as initial parasite 
concentration and incubation time, was based on the growth curve of promastigotes. 
Exponential phase occurred during the 3 first days of culture, so the exposition of the parasites 
to cyanobacteria extracts and natural based compounds was performed during 72hours.  
 
Figure 2 – Growth curve of Leishmania infantum 
  
 4.2.1.2. Viability assays   
 The search for new treatments against leishmaniasis has increased due to high frequency 
of drug resistance registered in endemics areas, side effects, and complications caused by 
coinfection with HIV(Almeida-Souza et al., 2016). Classic drugs used to treat leishmaniasis, 
such as antimonials and amphotericin B are considered toxic to some patients, justifying the 
rational search for new anti-leishmanial compounds (Yamamoto et al., 2015). 
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 The effect of cyanobacterial extracts on Leishmania infantum varied according to the 
strain. For strain LEGE06113 (Figure 3C) they have shown an increased on the parasite 
viability. A reduction was observed in LEGE06099 (both concentrations) (Figure 3A), 
LEGE06102 (0.1 µg/mL) Figure 3B), LEGE07167 (both concentrations) (Figure 3D).  
 Cyanobacterial strains LEGE06102 and LEGE07167 belong to Oscillatoria genera as 
well as some cyanobacteria species that were found to have antileishmanial activity in our 
review, referred in Table VI. The compounds of Oscillatoria species that in our review have 
shown inhibitory effects against Leishmania includes polyketides, cyclic hexapeptides, 
lipopeptides and cyclic peptides. Thus it might be interesting to confirm if in our results with the 
same genera strains, the inhibitory effect its due to the same class of compounds. 
 In addition, the same cyanobacterial genera and class of compounds have shown 
activity against Trypanossoma parasites (Table VIII) that belong to the same family of 
Leishmania. Thus, we can speculate that the mechanism of action of these cyanobacterial 
compounds might be similar between these two parasites. 
 The reduction of viability of L. infantum could be due to ultrastructural changes induced 
by the natural compounds tested, for example, round-shape morphology instead of a fusiform 
shape of viable parasites. This alteration is important at a pharmacological level since the cell 
membrane is essential in binding and entrance of Leishmania parasite into its host cell. There 
are other structure changes of the parasite that could lead to the death of the parasite such as 
cytoplasmic vacuolization, nuclear alteration (Almeida-Souza et al., 2016), complex 
mitochondria-kinetoplast could acquire a swelling-shape and exhibit blebs (Yamamoto et al., 
2015). In general, these natural compounds could conduce to an apoptose (programmed cell 
death) in promastigotes of L. infantum ( Dehkordi et al., 2013). To prove this theory it must be 
done morphological and biochemical studies. 
 Natural marine compounds with effect on Leishmania promastigotes coupled with 
low cytotoxicity for human cells are promising for harmless methods for the development of 
new therapeutics of leishmaniasis. In fact, it was found no cytotoxic effects in keratinocytes and 
fibroblasts (Alfeus, 2016) and a battery of human cancer cell lines (Costa et al., 2013). All these 
results demonstrate the bioactivity of the tested strains with selective targets.  
 Our approach was to determine the potential effect beginning with two extracts 
concentrations (1 µg/mL and 0.1 µg/mL). Thus, for the strain that have shown inhibitory effects, 
the next step should be the determination of IC50 index. 
 However, a positive result of a screening test against promastigotes is not enough as 
an indicator of potential drug action. Indeed, is necessary to confirm its activity against 
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intracellular amastigotes to relate the in vitro activity of a substance with its possible efficacy in 
vivo (Almeida-Souza et al., 2016).   
  
 
Figure 3 – Effect of cyanobacterial crude extracts (LEGE0699, LEGE06112, LEGE06113, LEGE07167) on the viability of 
Leishmania infantum (“C-“ negative control, “C+” positive control, “E_0.1” 0.1 µg/mL of cyanobacterial crude extract and “E_1”1 
µg/mL of cyanobaterial crude extract, “ * ” statistically significant differences between negative control cultures and parasites 
cultured with the tested compounds and “ º ” outliers). 
  
 4.2.2 Giardia  
 4.2.2.1 Parasite density optimization 
 Considering the determination of the initial parasite density for viability assays, better 
results were obtained with an initial concentration of 5x10
4 
parasites/mL. For this parasite 
concentration the amount of formed formazan crystals were enough to reach an optical density 
signal. The lower parasite concentration didn’t generate the purple color, and the higher 
concentration generated a signal too high to be detected. 
* * 
* 
* 
* 
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 4.2.2.2 Viability assays 
 The effect of cyanobacterial extracts presented in Table I varied according to the strain. 
For strains LEGE06113 and LEGE07175 an increased on the parasite viability was observed 
(Figure 4B and 4D). A reduction was observed with the strain LEGE06108 (at both 
concentrations) (Figure 4A). No effects were observed with the strain LEGE07167 (Figure 4C). 
 The strain that showed a reduction on the parasite viability, LEGE06108, may be 
interesting for a fractionation process in order to isolate bioactive compounds with potential in 
giardiasis treatment. Considering this strain no cytotoxic effects were observed keratinocytes 
and fibroblasts (Alfeus, 2016) and a battery of human cancer cell lines (Costa et al., 2015). 
Besides that, it was also registered a superoxide radical scavenging activity of 49.70% at 
10µg/mL (Alfeus, 2016). The reduction in the parasite activity may thus represent a production 
of compounds targeting different cells. On the contrary the strains LEGE06113 and 
LEGE07175 was already referred was found to induce cytotoxicity in cancer cell lines (Freitas, 
et al., 2015) and also not to be cytotoxic against normal cells such as keratinocytes and 
fibroblasts (Alfeus, 2016). All these results demonstrate the bioactivity of the tested strains with 
selective targets. By not being toxic to human cells the extract of strain LEGE06108 may be 
promising for a safely and effectively treatment of giardiasis.  
 Although the mechanism of action can’t be established, there are a few possibilities 
for the reduction in cell viability observed. In this case the reduction could be due to a loss in 
cell adhesion to the bottom of the wells. These compounds could lead to a loss of adhesion 
which would have therapeutic importance because that is essential for the colonization of 
Giardia, in the small intestine of the mammals. Besides that, the disk adhesion is considered to 
play a crucial role in the pathogenesis of giardiasis (Farthing, 1997). Other effects of these 
compounds could be on the structural level, for example, deformations in typical trophozoite 
appearance (often roundly shape), irregular dorsal and ventral surface, presence of membrane 
blebs, electrodense precipitates in cytoplasm and nuclei, internalization of flagella and plasmatic 
membrane alterations(Machado et al., 2010).  
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Figure 4 - Effect of cyanobacterial crude extracts (A-LEGE06108, B-LEGE06113, C-LEGE07167, D-LEGE07175) on the viability 
of Giardia duodenalis ( “C-“ negative control, “C+” positive control, “E_0.1” 0.1 µg/mL of cyanobaterial crude extract, “E_1” 1 
µg/mL of cyanobaterial crude extract final concentration, “ * ” statistically significant differences between negative control cultures 
and parasites cultured with the tested compounds and “ º ” outliers ). 
  
 Considering the cyanobacterial extracts presented in Table II, only one assay was 
performed and thus no statistical analysis comparing independent experiments was performed. 
In Figure 5 it is presented the results considering the viability of the parasites exposed to the 
cyanobacteria extracts.  
 According to these results none of the cyanobacterial strains induced a significative 
toxic effect, although a reduction in 20% was observed for strain LEGE06020 at the lowest 
concentration and LEGE00041 at the highest concentration.   
* * 
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Figure 5 – Percentage of Viability of Giardia duodenalis exposed to LEGE06104, LEGE06020, LEGE00038, LEGE00041, 
LEGE06361, LEGE11428. 
 
 Considering the effect of natural based compounds presented in Table III, it was 
evaluated their anti-parasitic activity against G. duodenalis. From results represented in figures 
6, 7 and 8 only compound AQ1812f27-28 (Figure 8A) induced a reduction on parasite viability 
(>50% and <75%), while others like LCL168R and LCL169R inhibit parasite growth about 
20% (Figure 6D, 6E). However there were no statistically significant differences between 
negative control cultures and parasites cultured with those and all the other tested compounds.  
 Some of these compounds like LCL168R (Figure 6D) are spiro oxindole derivates, a 
kind of substances found in nature for instance in marine products (Baran et al., 2007) . Indeed, 
spiro oxindoles have shown inhibition of other flagellated protozoan like Leishmania (Saha et 
al., 2016) as well as biological activity against helminthic parasites (Trost et al., 2013). 
 The synthetic spiro oxindole compounds tested (Table III) results from the combination 
of two potentially bioactive structural motifs: the spirooxindole substructure and the a-
alkylidene-g-butyrolactone moiet, as described by (Cerisoli et al., 2016b). Differences among 
those Natural based compoundsreside on the added radicals and/or position and conformational 
alterations (Table IV). So, in the case of LCL168R compound for instance (Figure 6D), the anti-
parasitic activity could eventually be increased by identifying the specific motif responsible for 
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Giardia inhibition and improving the chemical structure in order to achieve higher anti-parasitic 
activity. 
 Concerning the AQ1812f27-28 compound it belongs to a group of spirocyclic oxindoles 
that are considered privileged molecular structures associated with various compounds with 
potent pharmaceutical properties (Cerisoli et al., 2016b).  
 Regarding peroxide derivates (Figure 6G, H, I; Figure 7A, B, C, D) there was not 
observed an inhibitory effect on parasite growth. Several peroxide-containing metabolites 
belonging to the classes of terpenes, polyketides and phenolics have been isolated from marine 
organisms showing potent antimalarial activity (Meshnick et al., 1996). Inspired by the pool of 
natural peroxides, over the last three decades the scientific community has given special 
attention to the design, synthesis and development of fully synthetic peroxides such as 
tetraoxanes, trioxanes, dioxanes,among others. Quintavalla group was prompted by studies on 
the relatively simple structure of plakortin (Persico et al., 2011) to develop an approach to the 
synthesis of endoperoxides (Sonawane et al., 2015b).  
  
Figure 6 - Effect of marine natural based compounds from sponges(A- “AQ1972f39”; B- “AQ1974f13”; C- “LCL173R”; D- 
“LCL168R”; E- “LCL169R”; F- “DS-23”; G- “DS-139”; H- “DS-130”, I-“DS-131”) on the viability of Giardia duodenalis (“C-“ 
negative control, “C+” positive control, “E_1” 1 µg/mL, “ * ” statistically significant differences between negative control cultures 
and parasites cultured with the tested compounds and “ º ” outliers). 
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Figure 7 - Effect of marine natural based compounds from sponges (A- “DS-24”; B- “DS-215”; C- “DS-217”; D- “DS-221”; E- 
“AQ1963f50-51”; F- “AQ1964f43-51”; G- “AQ1865f33-38”; H- “AQ1851f23-25”; I- “AQ1829f13-16”) on the viability of Giardia 
duodenalis (“C-“ negative control, “C+” positive control, “E_1” 1 µg/mL, “ * ” statistically significant differences between negative 
control cultures and parasites cultured with the tested compounds and “ º ” outliers). 
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Figure 8 - Effect of marine natural based compounds from sponges (A- “AQ1812f27-28”; B- “AQ1872f20-24”; C- “AQ1893f44-
46”; D- “AQ1897f26-33”; E- “AQ1906f33-42”; F- “AQ1880f48-55”; G- “AQ1866f26-30”; H- “AQ1846f18”) on the viability of 
Giardia duodenalis (“C-“ negative control, “C+”positive control, “E_1” 1 µg/mL, “ * ” statistically significant differences between 
negative control cultures and parasites cultured with the tested compounds and “ º ” outliers). 
  
 4.2.3 Trichomonas 
 4.2.3.1 Culture Optimization 
 The conditions for the viability assay using Trichomonas parasites, such as initial 
parasite concentration and incubation time, was based on the growth curve of trophozoites 
(Figure 9). Exponential phase occurred during the 3 first days so the exposition of the parasites 
to cyanobacteria extracts and natural based compounds was performed during 72 hours. 
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             Figure 9 – Growth curve of Trichomonas vaginalis. 
  
 4.2.3.2 Viability assays  
  For specie Trichomonas vaginalis results showed no significative differences 
between negative control and parasites exposed to LEGE extracts represented in Table I (Figure 
10). The effect of the natural based compounds in Trichomonas vaginalis growth is represented 
in figures 11 and 12. Some compounds like AQ1897f26-33 and AQ1906f33-42 (Figure 13G,F)  
induced a slight decrease (>= 20% and <50%) in parasite viability. Nevertheless, this reduction 
was not statistically significative.  
 In the same way as Giardia results, some of these compounds could eventually be 
improved by synthetic manipulation of chemical structure in order to reach higher anti-parasitic 
activity. 
 Besides, it’s very important to have sensitive viability assays to detect differences that  
might not observed with MTT assay or other colorimetric tetrazolium reagents like MTS, XTT 
and WST-1. For instance, alternative methods such as resazurin reduction, protease substrates 
generating a fluorescent signal, the luminogenic ATP assay and a novel real-time method to 
monitor live cells in culture, could be an option, as they have shown high sensitivity (Riss et al., 
2004).  
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Figure 10 - Effect of cyanobacterial crude extracts (LEGE0699, LEGE06102, LEGE06113, LEGE06194, LEGE 07163, LEGE 
07167) on the of viability of Trichomonas vaginalis (“C-“ negative control, “C+” positive control, “E_1”1 µg/mL of sponge 
compounds, “ * ” statistically significant differences between negative control cultures and parasites cultured with the tested 
compounds and “ º ” outliers). 
 
Figura 11 - Effect of marine natural based compounds from sponges(A- “AQ1972f39”; B- “AQ1974f13”; C- “LCL173R”; D- 
“LCL168R”; E- “LCL169R”; F- “DS-23”; G- “DS-139”; H- “DS-130”, I- “DS-131”) on the viability of Trichomonas vaginalis  
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(“C-“ negative control, “C+” positive control, “E_1” 1 µg/mL, “ * ” statistically significant differences between negative control 
cultures and parasites cultured with the tested compounds and “ º ” outliers). 
 
 
 
Figure 12 - Effect of marine natural based compounds from sponges (A- “DS-24”; B- “DS-215”; C- “Ds-217”; D- “DS-221”; E- 
“DS-222”; F- “AQ1963f50-51”; G- “AQ1964f43-51”; H- “AQ1865f33-38”; I- “AQ1851f23-25”) on the viability of Trichomonas 
vaginalis (“C-“ negative control, “C+” positive control, “E_1” 1 µg/mL,  “ * ” statistically significant differences between negative 
control cultures and parasites cultured with the tested compounds and “ º ” outliers). 
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Figure 13  - Effect of marine natural based compounds from sponges (A- “AQ1829f13-16”; B- “AQ1812f27-28”; C- “AQ1872f20-
24”; D- “AQ1893f44-46”; E- “AQ1897f26-33”; F- “AQ1906f33-42”; G- “AQ1880f48-55”; H- “AQ1866f26-30”, I- “AQ1846f18” ) 
on the viability of Trichomonas vaginalis (“C-“ negative control, “C+”positive control, “E_1” 1 µg/mL, “ * ” statistically significant 
differences between negative control cultures and parasites cultured with the tested compounds and “ º ” outliers). 
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5. Conclusion 
 As far as we know from the bibliographic review, this was the first study where 
cyanobacterial extracts/compounds were tested against the parasite Giardia duodenalis and 
Trichomonas vaginalis.  
 Concerning to Giardia duodenalis, LEGE06108 seems to be an interesting 
cyanobacteria strain regarding its antiparasitic activity. Further studies should be performed to 
achieve the optimum extract concentration. In parallel and in order to identify the active 
compound or compounds, or either to detect synergism between compounds, it should be 
performed the fractionation of crude extracts by chromatographic analysis and test its individual 
activity.   
 In relation to Trichomonas vaginalis there wasn’t any cyanobacterial strain with 
inhibitory parasite effect. However, we only tested extracts from five cyanobacterial strains. So 
it would be important to evaluate the potential activity of the remaining six cyanobacterial 
strains. In addition and also for Giardia it should be done at least three assays to have a 
representative sample.  Consequently, further studies must be done so that on the one hand 
obtain fractions increasingly toxic until isolate the compound with anti-parasitic activity and on 
the other to achieve representative results Regarding to Leishmania infantum 
LEGE06099, LEGE06102, LEGE07167 cyanobacterial strains seem promising but should be 
tested against the intracellular amastigote to confirm their citotoxicity. 
 Regarding cyanobacterial strains that have not shown inhibitory effect, we cannot 
exclude its potential as antiparasitic. Crude extracts are a mixture of several compounds that 
individually could have some activity but together might be affected by other compounds 
presence. Ideally, each extract compound should be tested for their antiparasitic activity 
  
 About the natural based compounds tested, their synthetic manipulation it could be 
continued to conquer the chemical structure that can be toxic to the parasites in study.     
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